Ditchcarbon
  • Customers
  1. Organizations
  2. Akebia Therapeutics, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 5 months ago

Akebia Therapeutics, Inc.

Company website

Akebia Therapeutics, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with kidney disease. Founded in 2007, Akebia has made significant strides in the industry, particularly in the area of hypoxia-inducible factor (HIF) stabilisation, which plays a crucial role in managing anaemia associated with chronic kidney disease. The company’s flagship product, vadadustat, is designed to treat anaemia by stimulating erythropoiesis, offering a unique oral alternative to traditional injectable therapies. Akebia's commitment to advancing renal care has positioned it as a notable player in the biopharmaceutical landscape, with a strong emphasis on research and development. With a focus on improving patient outcomes, Akebia continues to explore new avenues in the treatment of kidney-related conditions, solidifying its reputation as an innovator in the field.

DitchCarbon Score

How does Akebia Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Akebia Therapeutics, Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.

30%

Let us know if this data was useful to you

Akebia Therapeutics, Inc.'s reported carbon emissions

Akebia Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Akebia may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As a biotechnology firm, Akebia operates within an industry that is increasingly recognising the importance of sustainability and climate action. However, without specific emissions data or reduction initiatives, it is challenging to assess their environmental impact or commitment to climate goals. The company may benefit from developing a comprehensive climate strategy to align with industry standards and expectations.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Akebia Therapeutics, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Akebia Therapeutics, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Akebia Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Teva Pharmaceuticals USA, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

FibroGen, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

AMAG Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 17 hours ago

Haleon plc

GB
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Rockwell Medical, Inc.

US
•
Health and social work services (85)
Updated 13 days ago

Fresenius Medical Care Holdings, Inc.

US
•
Health and social work services (85)
Updated 9 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250807.8
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy